NRIX Healthcare

Nurix Therapeutics, Inc.

$25.82+0.47%

Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 2.7B USD
Enterprise value: 2.3B USD
Full-time employees: 317

Overall health

Strength: more profitable than most peersmore profitable than peers
Drawback: its share price swings more than most peers’ (beta 1.82 vs a peer median of 0.63)bigger price swings (beta 1.82 vs peers 0.63)
About average: risk (debt, liquidity and share-price swings)risk

Ranks #9 of 1,157 healthcare companies (top 1%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 132% from November 2022 to September 2026.
Nurix Therapeutics had 132% more shares at September 2026 than at November 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Nurix Therapeutics had 132% more shares at September 2026 than at November 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Stock-based pay is a large cost. Stock pay was 45% of revenue in FY Nov 2025.
Nurix Therapeutics paid employees $38M in stock in FY Nov 2025, 45% of its $84M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Nurix Therapeutics made a profit per share in its latest year after a loss the year before.
Valuation signals disagree. Cheaper than 95% of peers on earnings, but only 0% on operating cash profit (EBITDA).Cheaper than 95% of peers on earnings, but only 0% on operating cash profit.
Relative to its earnings, Nurix Therapeutics looks cheaper than 95% of peers; relative to its operating cash profit (EBITDA), cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its earnings, Nurix Therapeutics looks cheaper than 95% of peers; relative to its operating cash profit, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

StockQuotient Score

84/ 100▲ 1 since Oct 27 close

Oct 5 17 → Nov 4 84 (+67)

Valuation

Is the price right?

75/100

Moderate▲ 2 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Share count up 5.3% (existing holders diluted)

Valuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 73 → 75

Peer companies moved+2

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield10.5%

SEC filings · 12 months to Aug 2026Reported value30% base weight · Z-score 6.07Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-15.4%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield13.1%

SEC filings · 12 months to Aug 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield34.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

98/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 1809.2%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth
▲ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a loss to a profit33% base weight · Z-score 4.46Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth117.1%

SEC filings · 3 years to Aug 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 8.59Sector median: 0.0584 · MAD: 0.0840

Revenue growth738.8%

SEC filings · 12 months to Aug 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 10.15Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

99/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Turned profitable over the last 12 months
Free cash flow turned positive over the last 12 months

Why

Stronger than most peers on:

▲ Operating margin
▲ ROA
▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin41.3%

SEC filings · 12 months to Aug 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.16Sector median: 0.0706 · MAD: 0.1217

Return on assets24.7%

SEC filings · 12 months to Aug 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.47Sector median: 0.0166 · MAD: 0.0537

Return on invested capital92.2%

SEC filings · 12 months to Aug 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 3.81Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity30.5%

SEC filings · 12 months to Aug 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Current ratio
▲ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.82

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -3.54Sector median: 0.6250 · MAD: 0.3380

Current ratio8.44×

SEC filings · latest balance sheetReported value33% base weight · Z-score 4.23Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.14×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.38Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Nurix Therapeutics

Is Nurix Therapeutics getting weaker?: Its latest SEC filing (Oct 13, 2026) was mixed: some things better, some worse: turned profitable over the last 12 months; share count up 5.3%. Its overall score is 84/100, up 1 since Oct 28, 2026.
How is Nurix Therapeutics valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 75/100 against 1,393 healthcare peers. Earnings yield 10.5% vs a peer median of 1.5% (stronger than 95% of peers).Earnings yield 10.5% vs peers 1.5% (stronger than 95% of peers). EBITDA yield -15.4% vs a peer median of 4.0% (weaker than 100% of peers).EBITDA yield -15.4% vs peers 4.0% (weaker than 100% of peers).
Is Nurix Therapeutics growing?: Yes, faster than most of its peers. Growth scores 98/100 against 1,393 healthcare peers. 3-year revenue growth 117.1% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 117.1% vs peers 5.8% (stronger than 95% of peers).
How profitable is Nurix Therapeutics?: More profitable than most of its peers. Profitability scores 99/100 against 1,393 healthcare peers. Operating margin 41.3% vs a peer median of 7.1% (stronger than 95% of peers).Operating margin 41.3% vs peers 7.1% (stronger than 95% of peers).
How risky is Nurix Therapeutics?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 8.44× vs a peer median of 2.59× (stronger than 85% of peers).Current ratio 8.44× vs peers 2.59× (stronger than 85% of peers). Beta 1.82 vs a peer median of 0.63 (weaker than 92% of peers).Beta 1.82 vs peers 0.63 (weaker than 92% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Aug 31, 2026 · filed Oct 13, 2026 · compared with the quarter ended May 31, 2026

Mixed: some things better, some worse

Turned profitable over the last 12 months
Share count up 5.3% (existing holders diluted)
Free cash flow turned positive over the last 12 months

	Previous quarter	Latest quarter	Change
Revenue (12 months)	36.8M USD	701.9M USD	+1809.2%
Net income (12 months)	−341.4M USD	294.9M USD	turned positive
Operating margin	-982.4%	41.3%	+1023.6 pts
Free cash flow (12 months)	−304.5M USD	369.8M USD	turned positive
Cash	67.7M USD	720.2M USD	+964.1%
Shares outstanding	103.8M	109.2M	+5.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Nov 2021	FY Nov 2022	FY Nov 2023	FY Nov 2024	FY Nov 2025	Change
Operating margin	-396.3%	-476.0%	-201.4%	-390.5%	-340.2%	▲ 50 pts
Net margin	-393.9%	-466.9%	-187.0%	-354.9%	-314.9%	▲ 40 pts
Return on assets (ROA)	-24.6%	-43.3%	-40.5%	-28.9%	-38.4%	▼ 9.5 pts
Return on equity (ROE)	-34.2%	-59.4%	-71.8%	-36.7%	-49.1%	▼ 12 pts
Free cash flow margin	-302.6%	-445.4%	-116.6%	-333.4%	-313.7%	▲ 20 pts
Current ratio	4.70×	4.51×	3.40×	6.46×	7.02×	▲ 8.6%

NRIX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: more profitable than most peersmore profitable than peers

Drawback: its share price swings more than most peers’ (beta 1.82 vs a peer median of 0.63)bigger price swings (beta 1.82 vs peers 0.63)

About average: risk (debt, liquidity and share-price swings)risk

Ranks #9 of 1,157 healthcare companies (top 1%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 132% from November 2022 to September 2026.

Nurix Therapeutics had 132% more shares at September 2026 than at November 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Nurix Therapeutics had 132% more shares at September 2026 than at November 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Stock-based pay is a large cost. Stock pay was 45% of revenue in FY Nov 2025.

Nurix Therapeutics paid employees $38M in stock in FY Nov 2025, 45% of its $84M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.

Nurix Therapeutics made a profit per share in its latest year after a loss the year before.

Valuation signals disagree. Cheaper than 95% of peers on earnings, but only 0% on operating cash profit (EBITDA).Cheaper than 95% of peers on earnings, but only 0% on operating cash profit.

Relative to its earnings, Nurix Therapeutics looks cheaper than 95% of peers; relative to its operating cash profit (EBITDA), cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its earnings, Nurix Therapeutics looks cheaper than 95% of peers; relative to its operating cash profit, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Questions investors ask about Nurix Therapeutics

Is Nurix Therapeutics getting weaker?

Its latest SEC filing (Oct 13, 2026) was mixed: some things better, some worse: turned profitable over the last 12 months; share count up 5.3%. Its overall score is 84/100, up 1 since Oct 28, 2026.

How is Nurix Therapeutics valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 75/100 against 1,393 healthcare peers. Earnings yield 10.5% vs a peer median of 1.5% (stronger than 95% of peers).Earnings yield 10.5% vs peers 1.5% (stronger than 95% of peers). EBITDA yield -15.4% vs a peer median of 4.0% (weaker than 100% of peers).EBITDA yield -15.4% vs peers 4.0% (weaker than 100% of peers).

Is Nurix Therapeutics growing?

Yes, faster than most of its peers. Growth scores 98/100 against 1,393 healthcare peers. 3-year revenue growth 117.1% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 117.1% vs peers 5.8% (stronger than 95% of peers).

How profitable is Nurix Therapeutics?

More profitable than most of its peers. Profitability scores 99/100 against 1,393 healthcare peers. Operating margin 41.3% vs a peer median of 7.1% (stronger than 95% of peers).Operating margin 41.3% vs peers 7.1% (stronger than 95% of peers).

How risky is Nurix Therapeutics?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 8.44× vs a peer median of 2.59× (stronger than 85% of peers).Current ratio 8.44× vs peers 2.59× (stronger than 85% of peers). Beta 1.82 vs a peer median of 0.63 (weaker than 92% of peers).Beta 1.82 vs peers 0.63 (weaker than 92% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

36.8M USD

701.9M USD

+1809.2%

Net income (12 months)

−341.4M USD

294.9M USD

turned positive

Operating margin

-982.4%

41.3%

+1023.6 pts

Free cash flow (12 months)

−304.5M USD

369.8M USD

turned positive

Cash

67.7M USD

720.2M USD

+964.1%

Shares outstanding

103.8M

109.2M

+5.3%

Key ratios

FY Nov 2021

FY Nov 2022

FY Nov 2023

FY Nov 2024

FY Nov 2025

Change

Operating margin

-396.3%

-476.0%

-201.4%

-390.5%

-340.2%

▲ 50 pts

Net margin

-393.9%

-466.9%

-187.0%

-354.9%

-314.9%

▲ 40 pts

Return on assets (ROA)

-24.6%

-43.3%

-40.5%

-28.9%

-38.4%

▼ 9.5 pts

Return on equity (ROE)

-34.2%

-59.4%

-71.8%

-36.7%

-49.1%

▼ 12 pts

Free cash flow margin

-302.6%

-445.4%

-116.6%

-333.4%

-313.7%

▲ 20 pts

Current ratio

4.70×

4.51×

3.40×

6.46×

7.02×

▲ 8.6%